Two Years After Launch of Genentech's Ocrevus, US Neurologists Report a Significant and Persistent Increase in the Treatment of Patients with Primary Progressive Multiple Sclerosis
Advertisement
According to a new report from Spherix Global Insights, Novartis' Mayzent is anticipated to grow the size of the secondary progressive multiple sclerosis segment in the United States, decreasing the influence of the relapsing remitting multiple sclerosis segment on market dynamics
